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Background: With the stage migration of prostate cancer witnessed in the late 1990’s and early 2000’s along with
the persistent morbidities associated with prostatectomy and radiation therapy, the concept of focal prostate
cancer treatment remains quite attractive. Herein we evaluate the tolerability and non-oncologic outcomes of a
highly select cohort of men that underwent focal cryoablation of the prostate for the treatment of localized
prostate cancer.
Methods: Pre-operatively, erectile function was assessed by SHIM questionnaire while voiding symptoms were
assessed by AUA symptom score. Twenty-six highly select patients (23 low-risk prostate cancer and 3 intermediate-
risk prostate cancer) with documented minimal disease on saturation prostate biopsy underwent focal cryoablation
of the prostate (24 hemi-ablation and 2 subtotal ablation). Subsequently, serum PSAs were obtained every 3
months for 2 years and then every 6 months thereafter. PSA failure was defined as an increase of 0.50 ng/ml over
nadir. Mean follow-up was 19.1 months. Subjective assessment of erectile function and voiding was assessed post-
operatively at each visit.
Results: Based on our PSA failure definition, 11.5% (3 patients) of the cohort experienced biochemical failure. In
two of the three patients, localized disease was detected on subsequent transrectal ultrasound guided biopsy.
These two patients went on to have favorable PSA nadirs after undergoing conventional definitive therapy (one
patient had external beam radiation and one patient had whole gland cryoablation). Within the study cohort, 27%
(7 patients) reported new post-operative erectile dysfunction requiring therapy while no patients reported new
post-operative urinary incontinence or worsening of voiding symptoms.
Conclusion: These preliminary results add to the expanding body of literature that the minimally invasive focal
cryosurgical ablation of the prostate is a safe procedure with few side effects. The true extent of cancer control
remains in question, but in highly select patients, favorable PSA kinetics have been demonstrated. If confirmed by
further studies with long-term follow-up, this treatment approach could have a profound effect on prostate cancer
management.
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In the era of PSA screening for prostate cancer, we have
witnessed a stage and grade migration leading to a high
proportion of men diagnosed with small volume, low-
risk prostate cancer (i.e., serum PSA < 10, Gleason 6,
T1c) [1,2]. Due to the non-aggressive nature of some
small volume, low-risk prostate cancers, the ideal man-
agement option is not known. Recognized management* Correspondence: charles.rosser@orlandohealth.com
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reproduction in any medium, provided the oroptions for this cohort include: active surveillance, brachy-
therapy, external beam radiation therapy, total gland
cryoablation and prostatectomy (retropubic, perineal and
robotic). In the highly select patient, cancer specific sur-
vival employing any of these treatment options is excel-
lent, however morbidity from these interventions can be
significant. Thus, the idea of treating only the cancer
within the prostate and sparing the non-cancerous tissue
is quite appealing, yet controversial.
As defined by the International Task Force on Prostate
Cancer and the Focal Lesion Paradigm, the goal of focald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 2 Demographics and preoperative characteristics
Variables





Pretreatment clinical stage n (%)
T1c 26 (100)
Gleason score in entry biopsy n (%)
3 + 3 25 (96)
3 + 4 1 (4)
PSA at pre-operative evaluation n (%)
</= 10 24 (92)
10-20 2 (8)
Entry staging biopsy (all patients)
Median performed, n (range) 40 (30-60)
Median cores positive for cancer, n (range) 4 (1-6)
Unilateral Cancer, n (%) 24 (92)
Bilateral Cancer, n (%) 2 (8)
Preoperative urinary continence, n (%) 26(100)
Preoperative SHIM score median, n (range) 20 (16-25)
Mean follow-up, months 19.1
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late(s) known disease and preserve(s) existing functions,
with the overall objective of minimizing lifetime morbid-
ity without compromising life expectancy” [3]. The Task
Force reported that the ideal candidate for focal therapy
is one with low-risk prostate cancer. These selection cri-
teria are illustrated in Table 1 [4]. Focal cryoablation of
the prostate, first reported by Onik et al., is a minimally
invasive treatment modality with encouraging prelimin-
ary biochemical efficacy results and reduced morbidity
compared to conventional treatment options [5]. Based
on the above findings, we have selectively performed
focal cryoablation of the prostate in 26 patients over the
past six years. Herein we evaluate the tolerability and
non-oncologic outcomes of a highly select cohort of
then who underwent focal cryoablation of the prostate
for the treatment of localized prostate cancer.
Methods
After MD Anderson Cancer Center Orlando Institutional
Review Board approval, medical records of 26 men who
had undergone focal cryoablation from January 2006 to
March 2012 were extensively reviewed. Preferentially, low-
risk prostate cancer patients (i.e., serum PSA </= 10.0 ng/
ml, Gleason <7, < cT2b; n = 23), were considered for focal
ablation, while only three intermediate-risk prostate can-
cer patients (i.e., serum PSA 10-20 ng/ml; n = 2 or Gleason
score 7; n = 1) underwent focal cryoablation of the pros-
tate. Clinic and hospital records were reviewed for pa-
tient demographics, disease characteristics, pre-operative
American Urological Association (AUA) symptom index
questionnaire and Sexual Health Inventory for Men
(SHIM), post-operative voiding and erectile function and
follow-up (Table 2).
Initially, 33 patients interested in focal cryoablation
were seen in our outpatient clinic for evaluation of low-
grade, low-stage prostate cancer confirmed on histologic
examination of outside pathologic slides. On average,
four weeks prior to focal cryoablation in the outpatient
setting, all patients underwent a modification of a 3D
mapping ultrasound guided transperineal prostate biopsy
[6] under monitored anesthesia care (MAC) to confirmTable 1 Ideal candidate for focal therapy
Serum PSA PSA < 10 ng/mL, PSAD < 0.15 ng/mL/g
Clinical stage T1NxMx or T2aNxMx
Pathologic evaluation/
Gleason score**
3 + 3 or less (no grade 4 or 5)
No more than 2 adjacent regions positive for
cancer
Total length of cancer <10 mm total and <7
mm in any 1 core; <1/3 of cores positive for
cancer
* Modified from Sartor et al., 2008 [4] **10 core minimum biopsy schema, plus
2 additional cores for every 10 g of prostate >40 g (max 18 cores).extent and location of tumor(s). Each biopsy specimen
was labeled with location and orientation, which allowed
precise localization of tumor burden within the prostate.
The saturation prostate biopsies confirmed low volume
disease in 26 patients who comprised our study cohort.
The Endocare’s Cryocare CS system with the variable
probes along with the urethral warmer was utilized (me-
dian number of 3 probes) on all cases. Focal cryoablation
was performed as previously described [5,7] by one sur-
geon (CJR) in an outpatient setting. Intra-operative flex-
ible cystoscopy was reserved only for patients, who were
noted to have severe voiding symptoms on their pre-
operative evaluation or if correct probe placement could
not be confirmed on real-time ultrasound. Injection of
30 ml of local anesthetic into Denoviller’s fascia to
anesthetize and hydrodissect the prostate from the rec-
tum prior to the initiation of the freeze cycles was
employed in all cases. Twenty-four patients underwent
hemi-ablative cryosurgery while the two with bilateral
disease underwent subtotal cryosurgery with an attempt
to spare the prostatic tissue that resides next to the
cavernosal nerve (Figure 1). After the procedure, 25
patients were discharged from post anesthesia care unit
to home with a Foley catheter in place for 7-10 days at
which time all catheters were successfully removed in
clinic. One patient was admitted for twenty-three hours
observation due to social reasons. Four weeks after
Focal Ablation Hemi-Ablation
Subtotal Ablation
Figure 1 Schematic depicting ‘focal’cryoablation. Ablation can
be of single target lesion, of specific side of prostate harboring the
cancer or of nearly the entire gland but sparing the posterior lateral
aspects were caversonal resides.
Figure 2 Biochemical disease free-survival of 26 patients
treated with focal cryoablation of the prostate.
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serum PSA.
Serum PSAs were monitored every 3 months for 2
years then every 6 months thereafter. In addition, year-
ly digital rectal examinations (DRE) were performed.
Biochemical failure (BCF) was defined as an increase in
serum PSA of 0.5 ng/ml over nadir [8]. Patients with
BCF and/or abnormal DRE were encouraged to undergo
a repeat transrectal ultrasound needle guided biopsy of
the prostate in hopes of identifying recurrent disease.
Patients were considered to be potent if they were able
to achieve erections sufficient for penetration and impo-
tent if they were unable to achieve erections sufficient
for penetration. Patients requiring any potency aids, in-
cluding phosphodiesterase inhibitors, pumps, and vac-
uum devices, were noted. Patients were considered
incontinent if they used any pads at any time. Mean
follow-up time was 19.1 months (range 2-52 months).
Follow-up data ≥1 year was available in 18 patients
(69%), 1-2 years in 8 patients (31%), 2-5 years in 9
patients (35%).
Results
Median prostatic volume was 33 grams. No compli-
cations were noted after 3D mapping ultrasound guided
transperineal prostate biopsy. A mean of 35 cores were
obtained in each patient during the saturation biopsy
with a median of 4 cores per patient being positive for
cancer. Only two patients were noted to have bilateral
disease, with the majority of disease unilateral and no
more than 2 cores positive on the contralateral side. The
24 (92%) patients, who had unilateral disease, under-
went hemi-cryoablation of the prostate, whereas 2 (8%)
patients had bilateral disease and underwent sub-total
cryoablation of the prostate. Demographics and disease
characteristics are summarized in Table 2. The medianage of the patients was 65 years. Ninety-two percent of
the patients were Caucasian. All patients had non-
palpable T1c cancer and 25 (96%) had Gleason 3 + 3 (6)
disease.
Three patients developed PSA recurrence in follow-up
(Figure 2). Specifics related to the three patients (11.5%)
with PSA recurrence are shown in Table 3. Only two of
these patients (8%) had biopsy confirmed localized dis-
ease (Gleason 6). These two patients with documented
local recurrence underwent salvage procedures (1-exter-
nal beam radiation, 1-whole gland cryoablation). After
salvage therapy, the serum PSA of these two patients
decreased to favorable nadirs. Oncologic and functional
outcomes are depicted in Table 4. There were no deaths,
nor development of locally advanced/metastatic disease.
The mean pre-operative SHIM score was 20. All
patients underwent ‘nerve-sparing’ focal ablation. Post-
operative erectile dysfunction, requiring treatment of
any kind, occurred in 7 patients (27%). These patients
had a significantly lower pre-operative SHIM score than
the 19 patients who did not require any treatment for
erectile dysfunction, 18.6 vs. 20.9, respectively, p = 0.015.
No patient was found to be impotent. Seventeen patients
had moderate voiding symptoms evident on AUA symp-
tom score prior to surgery. No patient had severe voiding
symptoms or incontinence prior to focal ablation. Urinary
continence was maintained in all 26 patients. One of the
patients requiring a subtotal cryoablation for bilateral dis-
ease developed postoperative urinary retention from a per-
sistent median lobe after ablation (pre-operative AUA
symptoms score 3). The median lobe required surgical
resection as an outpatient to alleviate urinary retention.
Focal cryoablation was well tolerated with only one patient
developing a post-operative urinary tract infection (cath-
eter associated) and another patient developing a transient
rash possibly from pre-operative antibiotics.




















(ng/ml) (ng/ml) (ng/ml) Recurrence (ng/ml)
1 6 8.8 Hemi-ablation 2.8 3.7 No Watchful Waiting 3.3 31
2 6 5.3 Hemi-ablation 3.1 4.2 Yes External beam
radiation
0.4 18
3 6 4.5 Hemi-ablation 1.7 3.1 Yes Whole gland
cryoablation
0.2 15
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Today, more low-volume, less aggressive prostatic cancers
are being detected [1,2]. For example, in a retrospective
study of 1,386 radical prostatectomies specimens, unilat-
eral disease was present in approximately 20% of the
specimens with many of these tumors being low volume
[9]. These low-volume, low-risk prostate cancers, may not
affect long-term survival, thus these men then have a
reasonable choice to pursue active surveillance [10] or
definitive treatment. While active surveillance may be
associated with increased anxiety, definitive therapy may
be associated with significant treatment related side
effects (e.g., voiding issues and erectile dysfunction) or
the unnecessary treatment of a non-aggressive, non-
lethal disease. The rationale for focal therapy is that it
offers similar oncologic efficacy to definitive therapy but
with reduced treatment morbidity, when applied to
highly select patients [3,11].
In the current study, only highly select patients, identi-
fied by transperineal saturation prostate biopsy were
offered focal cryoablation of the prostate. Intra-operative
and immediate post-operative complications were min-
imal. Median PSA nadir of the cohort was 1.8ng/ml. Using
a stringent PSA failure definition [8], three patients were
noted to have biochemical failure with local failureTable 4 Oncologic and functional outcomes
Variable n (%)
Oncologic




Erectile Dysfunction Requiring Treatment 7 (27)
Impotent 0 (0)
Urinary Continence 26 (z100)
Complications
Fistula 0 (0)
Urethral slough 0 (0)
Urinary Tract Infection (UTI) 1 (4)
Urinary retention 1 (4)
Rash 1(4)documented in two out of the three patients on prostate
biopsy. The patient without documented local failure but
PSA failure was noted to have a subsequent reduction and
stabilization in serum PSA. Of the two patients with
the local failures, one was treated with whole gland
cryoablation and one was treated with salvage external
beam radiation therapy.
The median pre-operative AUA symptoms score of the
cohort was nine. All patients were continent post-
operatively. Except for the patient who developed post-
operative urinary retention from an obstructing median
lobe of the prostate, no one reported worsening voiding
symptoms after focal cryoablation. All voiding symptoms
resolved in the patient with urinary retention after he
underwent a limited transurethral resection of the
median lobe of the prostate. As for erectile function,
the median pre-operative SHIM score was 20. Post-
operative erectile dysfunction, requiring treatment of
any kind, occurred in 7 patients (27%). These patients
had a significantly lower pre-operative SHIM score than
the 19 patients (73%) who did not require any treatment
for erectile dysfunction. Thus a reduction in the erectile
function may be expected in men undergoing focal abla-
tion, who pre-operatively report reduced erections.
Numerous studies have reported their small experi-
ence in focal cryoablation of the prostate (Table 5)
[7,12-15]. Our biochemical disease free survival rates,
potency rates and incontinence rates are comparable to
what has been reported in the literature. In a retrospective
study of 73 low-intermediate risk patients (i.e., PSA ≤ 20,
Gleason score ≤ 7, clinical stage T1-T2b) whom underwent
focal cryotherapy, after a median follow-up of 3.7 years,
12 patients (17%) had positive cancer biopsies post-
operatively, but only one (1.4%) of those was in the ipsilat-
eral, treated lobe. Biochemical disease free survival was
not addressed in this study. All patients were continent
after surgery, and of the patients who were potent pre-
operatively, 74% maintained their potency one year after
the procedure, and that number grew with time [2]. One
of the largest studies to address focal cryoablation of
the prostate is from the national Cryo On-line Database
(COLD) registry, an online retrospective database estab-
lished to collect cryoablation outcomes from patients
treated with primary, salvage and focal cryoablation. In
Table 5 Focal cryosurgery outcomes














25 2.3 (median) ASTRO criteria 84% (PSA Nadir >50%) 4% 71% 100% N/A
Ellis et al.,
2007 [12]





48 4.5 (mean) ASTRO criteria 94% (ASTRO) 0% 90% 100% N/A
Truesdale et al.,
2010 [13]
77 2 (median) Phoenix criteria 73% 4% N/A N/A N/A
Ward et al.,
2012 [14]





73 3.7 (median) ASTRO criteria N/A 1% 86% 100% N/A
Present Study 26 1.6 (mean) 0.5 ng/ml over
nadir [8]
88% 0% 73%* 100% 4%^
ASTRO criteria, 3 consecutive rises in the serum PSA after the post-radiation PSA nadir; Phoenix criteria, serum PSA nadir post-radiation + 2 ng/ml.
*, Remainder 27% potent with the use of pharmacologic or mechanical aids.
^, urinary retention.
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patients (median follow-up 1.8 years) in the database.
Biochemical disease free survival was found to be 75.7%.
Not all patients were biopsied postoperative, but those
who were had a 3.7% rate of local failure. Urinary contin-
ence was high, at 98.4%, and spontaneous erections were
maintained in 58.1% of patients [15].
Though the idea of only treating the cancer within the
prostate and sparing the non-cancerous tissue is quite
appealing, the medical community must continue to
push to gather higher level of evidence on key issues
related to focal therapy prior to widely offering this
novel technology. These key issues include: 1) can we
accurately identify index lesions by extensive mapping of
the prostate, 2) can we reliably image cancers within the
prostate, 3) what is the long-term efficacy of the technol-
ogy to eradicate cancer and 4) how to follow-up of
patients treated with focal therapy [11]. Hopefully, on-
going trials related to saturation prostate biopsy, prostate
imaging, and focal therapy will provide the much needed
evidence that focal therapy of the prostate is an onco-
logically effective therapy for highly-select patients inte-
rested in preserving urinary and erectile function.
Our study has several limitations. First, it is a small
retrospective study from a single surgeon. Second, follow-
up, though longer than in most focal cryoablation studies,
was limited (mean follow-up of 19.1 months). Next, pre-
operative and post-operative imaging was not incor-
porated into our algorithm due to the lack of accuracy of
current imaging modalities to identify focal lesions within
the prostate. Lastly, serum PSAs and digital rectal exami-
nations were the only methods employed to monitor treat-
ment efficacy. Though PSA and digital rectal examination
are excellent means to follow-up patients after prostatec-
tomy, whole gland irradiation and whole gland cryo-ablation, PSA and digital rectal examination after focal
therapy may underestimate the extent of persistent
diseases. PSA and digital rectal examination were shown
to be inaccurate in following low-risk prostate cancer
patients on a surveillance protocol, thus most surveillance
protocols will incorporate transrectal ultrasound needle
guided prostate biopsies in follow-up [16]. Moving for-
ward, attention must be given to offering prostate biopsies
to patients treated with focal therapy.Conclusions
In conclusion, these preliminary results add to the
expanding body of literature that the minimally invasive
focal cryosurgical ablation is a safe procedure with few
side effects. The true extent of cancer control remains
in question, but in highly select patients, favorable PSA
kinetics have been demonstrated. Focal cryotherapy
may fill a void in the management of low-risk prostate
cancer patients, who refuse active surveillance and who
want to avoid other definitive therapeutic options (pros-
tatectomy, external beam radiation, brachytherapy and
whole gland cryoablation) with potential increased risks
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